# Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
Canonical URL: https://biopharmsignal.com/news/TARS/tarsus-and-john-cena-partner-to-raise-awareness-of-demodex-blepharitis-a-common-eyelid-disease-affecting-approximately-25-million-americans
Ticker: TARS
Company: Tarsus Pharmaceuticals
Source: Tarsus Pharmaceuticals
Published: 2026-05-14 12:30 EST
Original Source URL: https://ir.tarsusrx.com
## Summary

Cena opens up about his experience living with Demodex blepharitis, a common eyelid disease caused by microscopic mites that live in and around the eyelashes This common and often overlooked condition is characterized by eyelid redness, itching and crusting, and the collaboration encourages people

## Article Body
Cena opens up about his experience living with Demodex blepharitis, a common eyelid disease caused by microscopic mites that live in and around the eyelashes This common and often overlooked condition is characterized by eyelid redness, itching and crusting, and the collaboration encourages people
## Recent Company News
- 2026-05-14 12:30 EST — [Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans](https://biopharmsignal.com/news/TARS/tarsus-and-john-cena-partner-to-raise-awareness-of-demodex-blepharitis-a-common-eyelid-disease-affecting-approximately-25-million-americans) — Source: Tarsus Pharmaceuticals
- 2026-05-06 20:05 EST — [Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements](https://biopharmsignal.com/news/TARS/tarsus-reports-first-quarter-2026-financial-results-and-recent-business-achievements) — Source: Tarsus Pharmaceuticals
- 2026-04-29 20:30 EST — [Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026](https://biopharmsignal.com/news/TARS/tarsus-to-report-first-quarter-2026-financial-results-on-wednesday-may-6-2026) — Source: Tarsus Pharmaceuticals
- 2026-03-31 12:30 EST — [Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease](https://biopharmsignal.com/news/TARS/tarsus-doses-first-participant-in-calliope-a-phase-2-clinical-trial-of-tp-05-lotilaner-a-novel-investigational-oral-tablet-for-the-potential-prevention-of-lyme-disease) — Source: Tarsus Pharmaceuticals
- 2026-03-23 12:30 EST — [TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus](https://biopharmsignal.com/news/TARS/tp-03-lotilaner-ophthalmic-solution-0-25-now-approved-in-china-for-the-treatment-of-demodex-blepharitis-triggering-a-15m-milestone-payment-to-tarsus) — Source: Tarsus Pharmaceuticals
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)